A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Phase 3
900
about 5.6 years
50–85
29 sites in CA, CO, CT +14
What this study is about
This trial is testing a treatment called prasinezumab compared to a placebo in people with early-stage Parkinson's disease. The goal is to see if prasinezumab helps manage symptoms, is safe, and how it works in the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Prasinezumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody
Primary: Time to Confirmed Motor Progression Event on Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score
Secondary: Change From Baseline in Motor Function as Measured by the MDS-UPDRS Part III off Medication Score, Percentage of Participants With Adverse Events of Special Interest (AESI), Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Neurology